Testosterone Cypionate vs Enclomiphene Citrate: Special Populations Head-to-Head

How Each Drug Works: The Mechanistic Fork in the Road

Testosterone cypionate is exogenous androgen replacement. Injecting it bypasses the hypothalamic-pituitary-gonadal (HPG) axis entirely, raising serum testosterone through a pharmacological depot rather than stimulating the body's own production. Within days of the first injection, LH and FSH drop toward zero via negative feedback, and testicular testosterone synthesis stops [1].

Enclomiphene citrate takes the opposite path. It is the trans-isomer of clomiphene and acts as a selective estrogen receptor modulator (SERM) at the hypothalamus, blocking estradiol's inhibitory signal and causing the pituitary to release more LH and FSH. The testes respond by making more testosterone internally. In a randomized controlled trial by Kim et al. (N=124, BJU Int 2016), enclomiphene raised mean serum testosterone from 217 ng/dL to 413 ng/dL while increasing LH and FSH, compared with testosterone gel, which suppressed both gonadotropins to near zero [2].

Why Mechanism Determines Population Fit

For primary hypogonadism (testicular failure), the testes cannot respond to LH regardless of how much the hypothalamus signals. Enclomiphene adds no benefit in that scenario. Testosterone cypionate is the rational choice.

For secondary hypogonadism (the pituitary or hypothalamus is under-signaling but the testes are intact), enclomiphene can restore the entire hormonal cascade with one oral tablet daily. That mechanistic advantage shapes every population-specific decision below.

Younger Men Seeking Fertility Preservation

This is the clearest population split in men's TRT. Testosterone cypionate is contraindicated as a primary strategy in men who want biological children.

What TC Does to Sperm

Exogenous testosterone suppresses FSH, which is required to support Sertoli cell function and spermatogenesis. Azoospermia develops in roughly 40% of men on TRT within 6 months, and oligospermia affects the majority of the remainder [3]. Recovery of sperm counts after stopping TC can take 6 to 24 months and is not guaranteed in all men, particularly after multi-year use.

The Endocrine Society's 2018 clinical practice guideline explicitly states: "We suggest against starting testosterone therapy in men who are planning fertility in the near term." [4]

What Enclomiphene Does to Sperm

Enclomiphene's FSH-preserving mechanism is directly protective for spermatogenesis. Kim et al. (2016) reported that enclomiphene-treated men maintained sperm concentrations above 15 million/mL across 12 weeks of treatment, while the testosterone gel arm showed a statistically significant decline (P<0.001) [2]. LH rose from a mean of 3.0 to 6.5 mIU/mL, and FSH rose from 3.1 to 5.9 mIU/mL in the enclomiphene group [2].

For a 28-year-old man with secondary hypogonadism who wants children within two years, enclomiphene is the only evidence-supported oral option that raises testosterone while keeping the fertility pathway open [4].

Men Over 65: The T-Trials Evidence

The Testosterone Trials (T-Trials) remain the largest and most rigorous set of RCTs evaluating testosterone therapy in older men. Published in the New England Journal of Medicine (2016), the coordinated trials enrolled 788 men aged 65 or older with serum testosterone below 275 ng/dL and one or more symptoms [1].

Sexual Function Outcomes in Older Men

Testosterone treatment (gel formulation, targeting serum T 500 to 1,000 ng/dL) produced a statistically significant improvement in sexual desire and erectile function scores compared with placebo at 12 months [1]. The Sexual Function Trial within T-Trials reported a mean increase of 1.2 points on the PDAS sexual desire domain (P<0.001) for the testosterone group [1].

Testosterone cypionate injections produce similar pharmacodynamic effects to gel in older men, though peak-trough fluctuation is larger with biweekly IM dosing. For men 65 and older with confirmed primary or mixed hypogonadism, TC remains a well-supported choice.

Enclomiphene in Older Men: A Gap in the Evidence

No large RCT has evaluated enclomiphene specifically in men over 65. Secondary hypogonadism becomes less common with age; primary testicular failure grows more prevalent. Because enclomiphene depends on functional testes, its efficacy may be blunted in older men with age-related Leydig cell decline.

Clinically, a man over 65 with a low LH and low testosterone could still respond to enclomiphene if his testes retain capacity. But the absence of trial data in this age group means TC carries stronger evidentiary support for older adults [1].

Obese Men and Men with Metabolic Syndrome

Obesity drives functional hypogonadism through two mechanisms: adipose aromatase converts testosterone to estradiol, raising estrogen feedback and suppressing LH; and insulin resistance may directly impair Leydig cell output. Both pathways are theoretically addressable with enclomiphene.

Enclomiphene's Advantage in Functional Hypogonadism

Because obesity-related hypogonadism is typically secondary (the HPG axis is suppressed by excess estrogen rather than by gland failure), enclomiphene's SERM mechanism targets the exact defect. A 2015 study published in the International Journal of Clinical Practice (Wiehle et al., N=45) found that 12.5 mg enclomiphene daily raised mean serum testosterone by 197 ng/dL from a baseline of 239 ng/dL in men with secondary hypogonadism, many of whom had elevated BMI [5].

Testosterone Cypionate in Obese Men: Polycythemia and Cardiovascular Risk

TC works in obese men, but the risks need quantification. Hematocrit elevation (polycythemia) occurs in up to 18% of men on injectable testosterone [6]. Obesity independently raises cardiovascular risk, and stacking exogenous androgens onto that baseline warrants careful monitoring of hematocrit, blood pressure, and lipid panels every 3 to 6 months per Endocrine Society guidance [4].

For an obese man with secondary hypogonadism who does not want injections and is not pursuing fertility, enclomiphene may be a lower-risk entry point. Weight loss of 10% body weight may normalize testosterone on its own, a point worth discussing before initiating either agent [7].

Men with Secondary Hypogonadism: The Target Population for Enclomiphene

Secondary hypogonadism is defined by low serum testosterone combined with low or inappropriately normal LH and FSH, indicating insufficient hypothalamic or pituitary drive. This is the population for which enclomiphene was developed and studied.

Distinguishing Primary from Secondary Before Prescribing

Ordering a morning total testosterone alongside LH and FSH costs under $40 at most reference labs and completely changes the prescribing decision. Men with LH below 1.5 mIU/mL and testosterone below 300 ng/dL are secondary hypogonad candidates for enclomiphene. Men with LH above 9 mIU/mL and low testosterone have primary failure and need TC [4].

Skipping this lab workup and defaulting to TC for every low-T presentation misses the subset of men who could restore their own hormone production without suppressing the HPG axis permanently.

Real-World Response Rates

In the Kim et al. (2016) RCT, 84% of enclomiphene-treated men achieved a serum testosterone above 300 ng/dL at week 12 compared with 86% in the testosterone gel arm, with the critical difference being preserved gonadotropin function in the enclomiphene group [2]. Symptom scores (ADAM questionnaire) improved comparably between groups [2].

The HealthRX clinical team uses the following decision framework when a man presents with low testosterone:

1. Confirm diagnosis: two morning total testosterone levels below 300 ng/dL.
2. Measure LH and FSH. If LH is low or inappropriately normal, classify as secondary.
3. If secondary and fertility-seeking: enclomiphene citrate 12.5 mg daily, recheck T and LH at 6 weeks.
4. If secondary and fertility-complete (or primary hypogonadism): testosterone cypionate 100 mg IM weekly or 200 mg every 2 weeks.
5. Recheck hematocrit, PSA, and serum T at 3 months for TC; recheck T, LH, FSH, and semen analysis at 3 months for enclomiphene.

Switching from Testosterone Cypionate to Enclomiphene Citrate

Men on long-term TC who want to restore fertility or transition off injections are increasingly asking about switching to enclomiphene. This is clinically feasible but requires a structured washout.

The Washout Period

After stopping TC, LH and FSH take roughly 3 to 6 months to recover to levels sufficient to stimulate the testes, depending on duration of prior TC use. For men on TC for more than 2 years, recovery may be slower and less complete. During this window, serum testosterone will drop, often below 200 ng/dL, causing symptomatic hypogonadism [8].

Some clinicians bridge with low-dose human chorionic gonadotropin (hCG, which mimics LH) at 500 IU every other day during the TC-to-enclomiphene transition to keep testicular testosterone synthesis active while the HPG axis reactivates. This strategy lacks large RCT support but is consistent with physiological principles and is used in fertility restoration protocols [8].

Who Should Not Switch

Men with confirmed primary hypogonadism (Klinefelter syndrome, bilateral orchitis, post-orchiectomy, radiation damage) will not respond to enclomiphene regardless of washout duration. Their testes cannot produce testosterone even with maximal LH stimulation. Switching these patients to enclomiphene results in symptomatic hypogonadism without benefit [4].

Monitoring After the Switch

After initiating enclomiphene following TC washout, check serum testosterone, LH, FSH, and estradiol at 6 weeks. If testosterone remains below 300 ng/dL at 12 weeks with adequate LH response (above 5 mIU/mL), the testes may lack sufficient reserve, and the patient should return to TC or another exogenous testosterone formulation.

Post-Vasectomy Men

Post-vasectomy hypogonadism is a specific scenario worth addressing. The vas deferens obstruction that follows vasectomy can provoke antisperm antibody formation and, in some men, contribute to reduced testicular function over time. For a post-vasectomy man who is not pursuing reversal and is fertility-complete, this consideration removes the main advantage of enclomiphene.

Testosterone cypionate is appropriate for symptomatic post-vasectomy men with confirmed low testosterone. The fertility-preservation argument for enclomiphene does not apply in this context, though enclomiphene still works mechanically if hypogonadism is secondary in origin.

Side Effect Profiles by Population

Testosterone Cypionate

• Polycythemia: hematocrit above 52% in up to 18% of men on injectable TC [6].
• Testicular atrophy: virtually universal with sustained use due to LH suppression.
• Acne and oily skin: more common with IM depot formulations than topical.
• Erythrocytosis risk is higher in men over 60 and in those with sleep apnea [4].
• PSA rise of 0.3 to 0.5 ng/mL on average, requiring baseline and follow-up measurement [1].

Enclomiphene Citrate

• Visual disturbances: rare, estimated below 1% in trials, but a class effect of SERMs requiring immediate discontinuation if they occur [9].
• Mood changes: some men report irritability, possibly from estrogen receptor blockade in the CNS.
• Elevated estradiol: paradoxically, enclomiphene raises LH, which raises testosterone, which aromatizes to estradiol. Monitoring estradiol at 6 weeks is standard practice.
• No injection-site reactions, no testicular atrophy, no polycythemia [2].

Cost and Access

Testosterone cypionate is generic, typically costing $30, $80 per month for the medication alone, plus clinic and monitoring fees. It requires a controlled substance prescription (Schedule III) and regular injections, which some men self-administer at home after instruction.

Enclomiphene citrate is not yet FDA-approved as of mid-2025. It is available through compounding pharmacies under physician prescription at approximately $50, $120 per month depending on the compounding pharmacy and dose. The NDA filed by Repros Therapeutics (now a subsidiary) was not approved by the FDA due to questions about clinical meaningfulness of endpoints, and the compound remains in regulatory limbo [10]. Prescribers ordering compounded enclomiphene must be aware of this status and document informed consent accordingly.

Summary Comparison Table

| Feature | Testosterone Cypionate | Enclomiphene Citrate | |---|---|---| | Route | IM injection | Oral tablet | | HPG axis effect | Suppresses LH/FSH | Stimulates LH/FSH | | Fertility impact | Eliminates spermatogenesis | Preserves or restores spermatogenesis | | Best for primary hypogonadism | Yes | No | | Best for secondary hypogonadism | Yes, but suppresses axis | Yes, preserves axis | | Testicular volume | Decreases | Maintains or increases | | Polycythemia risk | Up to 18% | Minimal | | FDA approval status | Approved | Not approved (compounded) | | Evidence in men 65+ | Strong (T-Trials) | Limited | | Cost per month (approx) | $30, $80 | $50, $120 |